QV Investors Inc. Has $214,000 Position in Johnson & Johnson (JNJ)

QV Investors Inc. increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 9.2% in the 4th quarter, HoldingsChannel reports. The firm owned 1,660 shares of the company’s stock after purchasing an additional 140 shares during the period. Johnson & Johnson makes up 0.0% of QV Investors Inc.’s investment portfolio, making the stock its 25th biggest position. QV Investors Inc.’s holdings in Johnson & Johnson were worth $214,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Horan Securities Inc. boosted its position in shares of Johnson & Johnson by 122.3% during the 4th quarter. Horan Securities Inc. now owns 438 shares of the company’s stock worth $56,000 after acquiring an additional 241 shares in the last quarter. Stuart Chaussee & Associates Inc. boosted its position in shares of Johnson & Johnson by 20.7% during the 4th quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock worth $60,000 after acquiring an additional 80 shares in the last quarter. FNY Investment Advisers LLC boosted its position in shares of Johnson & Johnson by 594.4% during the 4th quarter. FNY Investment Advisers LLC now owns 500 shares of the company’s stock worth $64,000 after acquiring an additional 428 shares in the last quarter. Selective Wealth Management acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth about $105,000. Finally, CKW Financial Group boosted its position in shares of Johnson & Johnson by 18.8% during the 4th quarter. CKW Financial Group now owns 810 shares of the company’s stock worth $105,000 after acquiring an additional 128 shares in the last quarter. 67.35% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson stock opened at $139.65 on Friday. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.99. The company has a quick ratio of 1.20, a current ratio of 1.47 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $372.15 billion, a PE ratio of 17.07, a PEG ratio of 2.42 and a beta of 0.68.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.03 by $0.07. Johnson & Johnson had a return on equity of 35.79% and a net margin of 17.99%. The business had revenue of $20.02 billion during the quarter, compared to the consensus estimate of $19.55 billion. During the same period in the previous year, the business earned $2.06 EPS. The business’s quarterly revenue was up .1% on a year-over-year basis. On average, equities research analysts expect that Johnson & Johnson will post 8.6 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 11th. Stockholders of record on Tuesday, May 28th will be issued a $0.96 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.90. This represents a $3.84 annualized dividend and a dividend yield of 2.75%. The ex-dividend date of this dividend is Friday, May 24th. Johnson & Johnson’s payout ratio is presently 44.01%.

JNJ has been the subject of several analyst reports. Citigroup lowered their price objective on Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating for the company in a research report on Wednesday, January 2nd. Zacks Investment Research cut Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Wednesday, January 16th. Morgan Stanley upped their price objective on Johnson & Johnson from $134.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 17th. Wells Fargo & Co reaffirmed an “outperform” rating and set a $152.00 price objective (down from $162.00) on shares of Johnson & Johnson in a research report on Monday, January 14th. Finally, Barclays reaffirmed an “equal weight” rating and set a $135.00 price objective (down from $137.00) on shares of Johnson & Johnson in a research report on Wednesday, January 23rd. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $146.40.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.chaffeybreeze.com/2019/04/26/qv-investors-inc-has-214000-position-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Why are gap-down stocks important?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.